Table 5.
Pre-salvage therapy disease and treatment characteristics for EBRT studies.
| First author/ country | Year | Design | TRS (mo)(range) | BCR definition | Age (years)(range) | PSA (ng/mL)(range) | ISUP | GS | % GS (≤7) | % GS (≥8) | Imaging for relapse | Biopsy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leroy (France) | 2017 | R | 65 (28-150) | Phoenix | 70 (58-82) | 2.5 (0-11.7) | NR | NR | NR | NR | C-PET, MRI | Yes (83%) |
| Fuller (USA) | 2020 | P | 98 (31-241) | Phoenix | 74 (50-89) | 3.97 (0.1-48.2) | 3 | 7 | 64 | 36 | MRI | Yes (100%) |
| Jereczek-Fossa (Italy) | 2018 | R | 99.7 (23-208) | Phoenix | 73.2 (52.6-81.7) | 3.89 (0.17-51.8) | 2/3 | 7 | NR | NR | C-PET, MRI, CT | Yes (44%) |
| Loi (Italy) | 2018 | R | 76 (9-205) | Phoenix | 76 (62-86) | 2.6 (1-30) | NR | NR | NR | NR | C-PET, MRI | NR |
| D'Agostino (Italy) | 2019 | R | 90 (26-138) | NR | 78 (69-85) | 3.2 (1.2-13.5) | NR | NR | NR | NR | C-PET | No |
| Pasquier (France) | 2019 | R | 90 (24-216) | Phoenix | 71.2 (56-86) | 4.3 (2.0-38.3) | 3 | 7 | 66 | 34 | C-PET, MRI | Yes (100%) |
| Scher (France) | 2019 | R | 82.5 (29-207) | Phoenix | 64 (49-77) | 3.1 (0.01-23.7) | NR | NR | NR | NR | C-PET, MRI | Yes (80%) |
| Cuccia (Italy) | 2020 | R | 69 (29-141) | Phoenix | 75 (65-89) | 1.79 (0.18-10) | NR | NR | NR | NR | C-PET/ PSMA-PET, MRI | No |
| Matrone (Italy) | 2020 | R | 60 (16.9-615.5) | Phoenix | 76 (56-89) | 2.6 (2-7.68) | 1 | 6 | NR | NR | MRI, C-PET | Yes (11%) |
| Caroli (Italy) | 2020 | R | NR | Phoenix | 75 (71-80) | 1.1 (0.82-2.59) | NR | NR | NR | NR | PSMA-PET | NR |
| Bergamin (Australia) | 2020 | P | 99.6 (54-163.2) | Phoenix | 72 (62-83) | 4.1 (1.1-16.6) | NR | NR | NR | NR | PSMA-PET | Yes (100%) |
BT, brachytherapy; HDR, high dose rate; LDR, low dose rate; PSA, prostate specific antigen; NR, not recorded; GS, Gleason score; TRS, median time from primary treatment to salvage therapy; mo, months; BCR, biochemical recurrence; ASTRO, American Society for Radiation Oncology; MRI, magnetic resonance imaging; NS, bone scan; CT, computed tomography; US, ultrasound; C-PET, Choline positron emission tomography; PSMA , prostate specific membrane antigen.
For TRS, age, PSA, ISUP and GS, the median scores are presented.